Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 2/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GHSR | Q92847 | 4/20 | 0.46 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.41 |
| ▸ | IL1B | P01584 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607484 | 1.00 | RHEB (0.47) | RHEBGRIN1GHSRMALT1SYK | |
| SCHEMBL3607487 | 1.00 | RHEB (0.47) | RHEBGRIN1GHSRMALT1SYK | |
| SCHEMBL3599303 | 0.93 | RHEB (0.50) | RHEBGRIN1GHSR | |
| SCHEMBL3599300 | 0.93 | RHEB (0.50) | RHEBGRIN1GHSR | |
| SCHEMBL3610141 | 0.93 | RHEB (0.50) | RHEBGRIN1GHSR | |
| SCHEMBL3595113 | 0.89 | GRIN1 (0.52) | RHEBGRIN1 | |
| SCHEMBL17206304 | 0.84 | GRIN1 (0.55) | RHEBGRIN1 | |
| SCHEMBL18520576 | 0.82 | GRIN1 (0.50) | RHEBGRIN1 | |
| SCHEMBL3609483 | 0.81 | KDM4E (0.49) | GHSRPBKPOLB | |
| SCHEMBL3609484 | 0.81 | KDM4E (0.49) | GHSRPBKPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | RHEB 2282/4885GRIN1 650/4885GHSR 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.